66 related articles for article (PubMed ID: 16395262)
1. Severity of primary MPGN, rather than MPGN type, determines renal survival and post-transplantation recurrence risk.
Little MA; Dupont P; Campbell E; Dorman A; Walshe JJ
Kidney Int; 2006 Feb; 69(3):504-11. PubMed ID: 16395262
[TBL] [Abstract][Full Text] [Related]
2. The Association of Class I and II Human Leukocyte Antigen Serotypes With End-Stage Kidney Disease Due to Membranoproliferative Glomerulonephritis and Dense Deposit Disease.
Afolabi H; Zhang BM; O'Shaughnessy M; Chertow GM; Lafayette R; Charu V
Am J Kidney Dis; 2024 Jan; 83(1):79-89. PubMed ID: 37739026
[TBL] [Abstract][Full Text] [Related]
3. Functional Magnetic Resonance Imaging to Monitor Disease Progression: A Prospective Study in Patients with Primary Membranoproliferative Glomerulonephritis.
Villa G; Daina E; Brambilla P; Gamba S; Leone VF; Carrara C; Rizzo P; Noris M; Remuzzi G; Remuzzi A; Caroli A
Nephron; 2024; 148(6):367-378. PubMed ID: 37926085
[TBL] [Abstract][Full Text] [Related]
4. Fibronectin glomerulopathy in a kidney allograft biopsy.
Klair N; Mahmood SB; El-Rifai R; Nast CC; Bu L; Bregman A
BMC Nephrol; 2023 Dec; 24(1):359. PubMed ID: 38053039
[TBL] [Abstract][Full Text] [Related]
5. Recurrence of type I membranoproliferative glomerulonephritis after renal transplantation: analysis of the incidence, risk factors, and impact on graft survival.
Andresdottir MB; Assmann KJ; Hoitsma AJ; Koene RA; Wetzels JF
Transplantation; 1997 Jun; 63(11):1628-33. PubMed ID: 9197358
[TBL] [Abstract][Full Text] [Related]
6. Recurrent membranoproliferative glomerulonephritis after kidney transplantation.
Lorenz EC; Sethi S; Leung N; Dispenzieri A; Fervenza FC; Cosio FG
Kidney Int; 2010 Apr; 77(8):721-8. PubMed ID: 20130531
[TBL] [Abstract][Full Text] [Related]
7. Clinical characteristics and outcomes of immune-complex membranoproliferative glomerulonephritis and C3 glomerulopathy in Japanese children.
Ueda C; Horinouchi T; Inoki Y; Ichikawa Y; Tanaka Y; Kitakado H; Kondo A; Sakakibara N; Nagano C; Yamamura T; Fujimura J; Kamiyoshi N; Ishimori S; Ninchoji T; Kaito H; Shima Y; Iijima K; Nozu K; Yoshikawa N
Pediatr Nephrol; 2024 Apr; ():. PubMed ID: 38662234
[TBL] [Abstract][Full Text] [Related]
8. Demographic, clinical characteristics and treatment outcomes of immune-complex membranoproliferative glomerulonephritis and C3 glomerulonephritis in Japan: A retrospective analysis of data from the Japan Renal Biopsy Registry.
Nakagawa N; Mizuno M; Kato S; Maruyama S; Sato H; Nakaya I; Sugiyama H; Fujimoto S; Miura K; Matsumura C; Gotoh Y; Suzuki H; Kuroki A; Yoshino A; Nakatani S; Hiromura K; Yamamoto R; Yokoyama H; Narita I; Isaka Y
PLoS One; 2021; 16(9):e0257397. PubMed ID: 34520493
[TBL] [Abstract][Full Text] [Related]
9. Primary membranoproliferative glomerulonephritis in Sfax, Tunisia: epidemiologic profile and prognostic factors.
Agrebi I; Kammoun K; Dammak N; Hachicha J; Boudawara T; Jarraya F; Hmida MB
Pan Afr Med J; 2021; 38():218. PubMed ID: 34046124
[TBL] [Abstract][Full Text] [Related]
10. Long-Term Outcomes of C3 Glomerulopathy and Immune-Complex Membranoproliferative Glomerulonephritis in Children.
Kirpalani A; Jawa N; Smoyer WE; Licht C;
Kidney Int Rep; 2020 Dec; 5(12):2313-2324. PubMed ID: 33305125
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcomes of patients with end-stage kidney disease due to membranoproliferative glomerulonephritis: an ANZDATA registry study.
Wilson GJ; Cho Y; Teixiera-Pinto A; Isbel N; Campbell S; Hawley C; Johnson DW
BMC Nephrol; 2019 Nov; 20(1):417. PubMed ID: 31752734
[TBL] [Abstract][Full Text] [Related]
12. Complement-mediated renal diseases after kidney transplantation - current diagnostic and therapeutic options in
Abbas F; El Kossi M; Kim JJ; Shaheen IS; Sharma A; Halawa A
World J Transplant; 2018 Oct; 8(6):203-219. PubMed ID: 30370231
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcomes of kidney transplant recipients with end-stage kidney disease attributed to presumed/advanced glomerulonephritis or unknown cause.
Lim WH; Wong G; McDonald SP; Chakera A; Luxton G; Isbel NM; Pilmore HL; Barbour T; Hughes P; Chadban SJ
Sci Rep; 2018 Jun; 8(1):9021. PubMed ID: 29899355
[TBL] [Abstract][Full Text] [Related]
14. Case Report of Spontaneous Remission of Biopsy-Proven Idiopathic Immune Complex-Mediated Membranoproliferative Glomerulonephritis.
Shah R; Segal MS; Wilkowski MJ
Case Rep Nephrol Dial; 2017; 7(2):81-90. PubMed ID: 28868298
[TBL] [Abstract][Full Text] [Related]
15. Mycophenolate mofetil as a possible therapeutic option for idiopathic membranoproliferative glomerulonephritis.
Kazory A; Racusen LC; Berliner AR; Gimenez LF; Jaar BG
NDT Plus; 2008 Dec; 1(6):466-468. PubMed ID: 28656986
[No Abstract] [Full Text] [Related]
16. Rituximab for Treatment of Membranoproliferative Glomerulonephritis and C3 Glomerulopathies.
Rudnicki M
Biomed Res Int; 2017; 2017():2180508. PubMed ID: 28573137
[TBL] [Abstract][Full Text] [Related]
17. Complement related kidney diseases: Recurrence after transplantation.
Salvadori M; Bertoni E
World J Transplant; 2016 Dec; 6(4):632-645. PubMed ID: 28058212
[TBL] [Abstract][Full Text] [Related]
18. Selection of Patients for Initial Clinical Trials of Solid Organ Xenotransplantation.
Cooper DKC; Wijkstrom M; Hariharan S; Chan JL; Singh A; Horvath K; Mohiuddin M; Cimeno A; Barth RN; LaMattina JC; Pierson RN
Transplantation; 2017 Jul; 101(7):1551-1558. PubMed ID: 27906824
[TBL] [Abstract][Full Text] [Related]
19. Reclassification of membranoproliferative glomerulonephritis: Identification of a new GN: C3GN.
Salvadori M; Rosso G
World J Nephrol; 2016 Jul; 5(4):308-20. PubMed ID: 27458560
[TBL] [Abstract][Full Text] [Related]
20. Kidney transplant outcomes in familial C3 glomerulopathy.
Wong L; Moran S; Lavin PJ; Dorman AM; Conlon PJ
Clin Kidney J; 2016 Jun; 9(3):403-7. PubMed ID: 27274824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
